Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.

Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell EG.

J Law Med Ethics. 2019 Sep;47(3):430-441. doi: 10.1177/1073110519876176.

PMID:
31560634
2.

Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem.

Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ.

Drug Saf. 2019 Nov;42(11):1287-1295. doi: 10.1007/s40264-019-00849-8.

PMID:
31302895
3.

Children and Adults With Rare Diseases Need Innovative Medical Devices.

Peiris V, Xu K, Agler HL, Chen EA, Gopal-Srivastava R, Lappin BM, Lewis DY, Rao GR.

J Med Device. 2018 Sep;12(3):0347011-347018. doi: 10.1115/1.4040489. Epub 2018 Jul 13.

4.

Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis.

Sinha MS, Freifeld CC, Brownstein JS, Donneyong MM, Rausch P, Lappin BM, Zhou EH, Dal Pan GJ, Pawar AM, Hwang TJ, Avorn J, Kesselheim AS.

JMIR Public Health Surveill. 2018 Jan 5;4(1):e1. doi: 10.2196/publichealth.7823.

5.

Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.

Kesselheim AS, McGraw SA, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG.

Drug Saf. 2017 Jun;40(6):531-542. doi: 10.1007/s40264-017-0516-3.

PMID:
28247279
6.

Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.

Drug Saf. 2015 Sep;38(9):845. doi: 10.1007/s40264-015-0329-1. No abstract available.

PMID:
26201399
7.

Methodological approaches to evaluate the impact of FDA drug safety communications.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.

Drug Saf. 2015 Jun;38(6):565-75. doi: 10.1007/s40264-015-0291-y. Erratum in: Drug Saf. 2015 Sep;38(9):845.

PMID:
25968811
8.

Developing and Initiating Validation of a Model Opioid Patient-Prescriber Agreement as a Tool for Patient-Centered Pain Treatment.

Ghods MP, Schmid IT, Pamer CA, Lappin BM, Slavin DC.

Patient. 2015 Aug;8(4):349-58. doi: 10.1007/s40271-014-0094-8.

PMID:
25344927
9.

Israel's community workers in the aftermath of war.

Lappin B.

Ment Health Soc. 1974;1(3-4):213-27. No abstract available.

PMID:
4469349

Supplemental Content

Loading ...
Support Center